1. Microencapsulated rhEGF to facilitate epithelial healing and prevent scar formation of cesarean wound: A randomized controlled trial
- Author
-
Chuan-Chi Kao, Shin-Yin Huang, Chi-Hsin Chiang, Chih-Hui Lin, and Ting-Chang Chang
- Subjects
Cesarean section ,Recombinant human epidermal growth factor ,rhEGF ,Microencapsulated ,Scar ,Gynecology and obstetrics ,RG1-991 - Abstract
Objective: Cesarean section (CS) is a major surgical intervention that affects women at childbearing age. Scarring from CS potentially causes discomfort and psychological distress. Emerging evidence indicates that epidermal growth factor (EGF) plays crucial roles in wound healing with the potential of minimizing scar formation. This study aims to investigate the effect of microencapsulated recombinant human EGF (Me-EGF) in scar prevention. Silicone gel was incorporated as part of the routine scar treatment. Materials and methods: Healthy women scheduled for cesarean delivery were enrolled and randomized to three groups: (1) no scar treatment, (2) silicone gel only, or (3) silicone gel plus Me-EGF. Vancouver Scar Scale (VSS: vascularity, pigmentation, elasticity, and height) was used for scar assessment at the 6th month and 9th month after CS. Results: A total of 60 women were enrolled, but one patient withdrew due to noncompliance with the follow-up visit requirement. Me-EGF-containing treatment group consistently scored the lowest on every parameter in the VSS scale, followed by silicone gel group, and the group with no scar treatment. Kruskal–Wallis tests indicated significant differences (p
- Published
- 2021
- Full Text
- View/download PDF